tiprankstipranks
Trending News
More News >

Fusen Pharmaceutical Issues Profit Warning Amid Increased Losses

Story Highlights
  • Fusen Pharmaceutical anticipates significant losses for FY2024 due to industry challenges.
  • Increased R&D expenses and impairment losses contribute to Fusen’s financial downturn.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Fusen Pharmaceutical Issues Profit Warning Amid Increased Losses

Don’t Miss TipRanks’ Half-Year Sale

Fusen Pharmaceutical Co., Ltd. ( (HK:1652) ) just unveiled an announcement.

Fusen Pharmaceutical Co., Ltd. has issued a profit warning for the fiscal year ending December 31, 2024, anticipating a significant increase in losses compared to the previous year. The expected loss, ranging from RMB170 million to RMB210 million, is attributed to industry-wide inventory destocking, increased R&D expenses, and an impairment loss on an associate company. Despite these challenges, the company maintains a stable gross profit margin. Stakeholders are advised to exercise caution when dealing with the company’s securities.

More about Fusen Pharmaceutical Co., Ltd.

Fusen Pharmaceutical Co., Ltd. is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. The company focuses on research and development, manufacturing, and sales of pharmaceutical products.

YTD Price Performance: -65.00%

Average Trading Volume: 442,833

Technical Sentiment Consensus Rating: Buy

Current Market Cap: HK$227.9M

See more data about 1652 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1